Hyperpigmentation Disorders Treatment Market - Growing Demand Analysis and Trends 2019 to 2030

Market Industry Reports (MIR) has published a new report titled “Hyperpigmentation Disorders Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030.” According to the report, the global hyperpigmentation disorders treatment market is estimated to be over US$ 3.5 Bn in 2017. It is anticipated to grow at a CAGR of 7.0% from 2019 to 2030.

Increasing awareness among patients, technological advancements in the sector of aesthetic treatment of pigmentation related conditions, and growing geriatric population have been pivotal in dictating the growth of the hyperpigmentation disorders treatment market. Moreover, rising adoption of minimally invasive procedure, increasing medical tourism for aesthetics is anticipated to be the major drive the growth of the global hyperpigmentation disorders treatment market between 2019 and 2030.

Get FREE Sample Copy with TOC to understand the structure of the complete report @ https://www.marketindustryreports.com/pdf/36

Major Players in the Hyperpigmentation Disorders Treatment Market

The prominent players in the global Hyperpigmentation Disorders Treatment market are Bayer AG, RXi Pharmaceuticals, ALLERGAN, Galderma laboratories, SkinCeuticals International, PIERRE FABRE GROUP, EpiPharm AG, Obagi Cosmeceuticals LLC., and VIVIERPHARMA among others

Increasing Adoption of Minimally-Invasive Procedures

Since the advent of minimally-invasive procedures, the adoption of such procedures have witnessed substantial growth in recent times. Shorter hospital admittance time, lesser procedure associated pain and fewer complications have been pivotal in contributing to the growing adoption of minimally-invasive procedures.

According to the American Society of Plastic Surgeons (ASPS), the numbers of Americans opting for minimally-invasive cosmetic procedures have witnessed a growth of nearly 200% since 2000. In 2017, the total number of cosmetic procedures performed in U.S. was nearly 1.8 million. Growing preference for minimally-invasive cosmetic procedures in anticipated to further propel the growth of the hyperpigmentation disorders treatment market.